150 related articles for article (PubMed ID: 33834463)
1. [Identification of TCF3-ZNF384 fusion by transcriptome sequencing in B cell acute lymphoblastic leukemia and its laboratory and clinical characteristics].
Wu Q; Wang F; Yang J; Chen X; Ma X; Cao P; Zhang Y; Nie D; Chen J; Zhou X; Fang J; Liu M; Zhang M; Wu P; Wang T; Liu H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2021 Apr; 38(4):351-354. PubMed ID: 33834463
[TBL] [Abstract][Full Text] [Related]
2. Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia.
Oberley MJ; Gaynon PS; Bhojwani D; Pulsipher MA; Gardner RA; Hiemenz MC; Ji J; Han J; O'Gorman MRG; Wayne AS; Raca G
Pediatr Blood Cancer; 2018 Sep; 65(9):e27265. PubMed ID: 29797659
[TBL] [Abstract][Full Text] [Related]
3. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
Hirabayashi S; Ohki K; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yaguchi A; Terada K; Saito Y; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fujimura J; Hino M; Kinoshita A; Kakuda H; Kurosawa H; Kato K; Kajiwara R; Moriwaki K; Morimoto T; Nakamura K; Noguchi Y; Osumi T; Sakashita K; Takita J; Yuza Y; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Fukushima T; Koh K; Manabe A; Ohara A; Kiyokawa N;
Haematologica; 2017 Jan; 102(1):118-129. PubMed ID: 27634205
[TBL] [Abstract][Full Text] [Related]
4. ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B-cell acute lymphoblastic leukemia.
Shi ZY; Wang X; Chen WM; Li LD; Hao Y; Li JY; Sun K; Zhao XS; Jiang H; Jiang Q; Huang XJ; Qin YZ
Hematol Oncol; 2024 Jan; 42(1):e3251. PubMed ID: 38287528
[TBL] [Abstract][Full Text] [Related]
5. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
Zhou B; Chu X; Tian H; Liu T; Liu H; Gao W; Chen S; Hu S; Wu D; Xu Y
Am J Hematol; 2021 Nov; 96(11):1461-1471. PubMed ID: 34406703
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
[TBL] [Abstract][Full Text] [Related]
7. Frequency and outcome of pediatric acute lymphoblastic leukemia with ZNF384 gene rearrangements including a novel translocation resulting in an ARID1B/ZNF384 gene fusion.
Shago M; Abla O; Hitzler J; Weitzman S; Abdelhaleem M
Pediatr Blood Cancer; 2016 Nov; 63(11):1915-21. PubMed ID: 27392123
[TBL] [Abstract][Full Text] [Related]
8. Leukemia With
Lin N; Yan X; Cai D; Wang L
Front Oncol; 2021; 11():709036. PubMed ID: 34395283
[TBL] [Abstract][Full Text] [Related]
9. TCF3 gene rearrangements in pediatric B-cell acute lymphoblastic leukemia-A single center experience.
Zerkalenkova E; Menchits Y; Borkovskaia A; Sokolova S; Soldatkina O; Mikhailova E; Popov A; Komkov A; Rumiantseva Y; Karachunskii A; Olshanskaya Y
Int J Lab Hematol; 2023 Aug; 45(4):533-540. PubMed ID: 37058324
[TBL] [Abstract][Full Text] [Related]
10. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
Chen YH; Zhang X; Cheng YF; Chen H; Mo XD; Yan CH; Chen Y; Han W; Sun YQ; Wang Y; Zhang XH; Xu LP; Liu KY; Yang J; Zhang J; Zhang GL; Shi Y; Su YC; Li WQ; Xu L; Song D; Zhang M; Lu P; Huang XJ
Cytotherapy; 2020 Dec; 22(12):755-761. PubMed ID: 32861622
[TBL] [Abstract][Full Text] [Related]
12. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
13. [Chimeric antigen receptors T cells in treatment of a relapsed pediatric acute lymphoblastic leukemia, relapse after allogenetic hematopoietic stem cell transplantation: case report and review of literature review].
Zuo Y; Wang J; Lu A; Jia Y; Wu J; Dong L; Chang L; Zhang L
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):115-8. PubMed ID: 27014980
[TBL] [Abstract][Full Text] [Related]
14. T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation for a Patient With Tcf3-Hlf-Positive Acute Lymphoblastic Leukemia Extramedullary Relapse After Unrelated Bone Marrow Transplantation.
Takahashi N; Mochizuki K; Kobayashi S; Ohara Y; Kudo S; Saito Y; Ikeda K; Ohto H; Kikuta A; Sano H
J Pediatr Hematol Oncol; 2023 Apr; 45(3):e419-e422. PubMed ID: 36162014
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Significance of
Qin YZ; Jiang Q; Xu LP; Wang Y; Jiang H; Dao FT; Chen WM; Zhao XS; Liu YR; Zhang XH; Liu KY; Huang XJ
Front Oncol; 2021; 11():632532. PubMed ID: 33816270
[TBL] [Abstract][Full Text] [Related]
16. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
[No Abstract] [Full Text] [Related]
17. MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-Cell Therapy Bridging to Allogeneic Stem Cell Transplantation.
Zhang XY; Dai HP; Zhang L; Liu SN; Dai Y; Wu DP; Tang XW
Onco Targets Ther; 2021; 14():5197-5204. PubMed ID: 34744437
[No Abstract] [Full Text] [Related]
18. [Efficacy of CD19 Chimeric Antigen Receptors T Cells in the Treatment of Relapsed Patients with B Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation].
Chen HR; Zhang Y; Chen P; Liu XD; Huang Q; Zhang J; Li HM; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1040-1045. PubMed ID: 31418354
[TBL] [Abstract][Full Text] [Related]
19. Detection of EP300-ZNF384 fusion in patients with acute lymphoblastic leukemia using RNA fusion gene panel sequencing.
Jing Y; Li YF; Wan H; Liu DH
Ann Hematol; 2020 Nov; 99(11):2611-2617. PubMed ID: 32980888
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
